@FierceBiotech: A future threat to Provenge? Researchers target multiple tumors (prostate, lung, others) in new cancer vaccine study. Article | Follow @FierceBiotech
@JohnCFierce: Interesting note: Abingworth, a major Avila investor, also cashed out of Intellikine ($310M) in Dec. For VCs, M&A is key this year. | Follow @JohnCFierce
@MarkHFierce: Obama is pushing (again) for more funding for basic research. Is anybody going to listen this time? More | Follow @MarkHFierce
> The antibacterial drug developer Trius Therapeutics ($TSRX) is offering 8.6 million shares at a discount. Report
> Vanda Pharmaceuticals says its reaped some early efficacy data on four patients enrolled in its Phase III study for tasimelteon, a treatment designed to reset the body's biological clock. Release
Pharma News
@FiercePharma: $BMY earnings might have disappointed analysts--and Plavix is faltering--but newer meds grew--Bloomberg. Article | Follow @FiercePharma
> Abbott's round of 700 layoffs doesn't spare pharma. Story
> Ranbaxy faces 'groundbreaking' oversight with DoJ settlement. Item
> Bristol-Myers' Q4 shows growth in newer products. Report
Vaccines News
> Common chemicals threaten childhood vaccines. Story
> Researchers target multiple tumors in new cancer vaccine study. More
> Nanoparticles hijack immune response. Article
> Late-stage Galena vax offers hope for breast cancer patients. Story
Pharma Manufacturing News
> Owner arrested in Pakistani drug deaths cites Big Pharma conspiracy. Article
> Abbott includes manufacturing in 700 job cuts. News
> Warnings analysis spotlights analytics weakness. Story
> Merck 'program of projects' earns facility award. More
And Finally... A new study from Johns Hopkins shows that a doctor's weight could influence how they diagnose obesity in their patients. Release